Patents by Inventor Richard Ian Christopherson

Richard Ian Christopherson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8623356
    Abstract: The present invention relates generally to a set of synthetic immunointeractive molecules referred to herein as “demibodies” which are useful in targeting particular cells in a subject. More particularly, the present invention provides a set of demibodies wherein at least two molecules from within the set, each specific for a different antigen on a target cell, are required to interact together at the cell surface in order to form an active complex which directs demibody-mediated cellular or complement mediated cytotoxicity and/or reporter function and/or therapeutic activity. The demibodies of the present invention are useful in the targeting of particular cells such as cancer cells including leukemic cells, pathogens including malarial, bacterial and viral agents, and stem cells including embryonic and adult stem cells and pathogen cells. The present invention provides, therefore, methods of treatment, diagnosis and undertaking research and compositions comprising demibodies useful for same.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: January 7, 2014
    Assignee: The University of Sydney
    Inventors: Richard Ian Christopherson, Jacqueline Mary Matthews, Joel Peter MacKay
  • Patent number: 7560226
    Abstract: A method can identify a type of leukemia in a human subject. A biological sample from the human subject that contains CD antigens is obtained. The sample is contacted with an array of immunoglobulin molecules. Each immunoglobulin in the array, with the exception of one or more negative controls, is capable of interaction with a CD antigen on one or more types of leukemia cells. The pattern of interaction between the immunoglobulin molecules and the CD antigens in said sample is then determined, thereby providing an immunophenotype of the cells which is characteristic of the type of leukemia.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: July 14, 2009
    Assignee: Medsaic Pty Limited
    Inventors: Richard Ian Christopherson, Cristobal Guillermo Dos Remedios
  • Publication number: 20090130106
    Abstract: The present invention relates generally to a set of synthetic immunointeractive molecules referred to herein as “demibodies” which are useful in targeting particular cells in a subject. More particularly, the present invention provides a set of demibodies wherein at least two molecules from within the set, each specific for a different antigen on a target cell, are required to interact together at the cell surface in order to form an active complex which directs demibody-mediated cellular or complement mediated cytotoxicity and/or reporter function and/or therapeutic activity. The demibodies of the present invention are useful in the targeting of particular cells such as cancer cells including leukemic cells, pathogens including malarial, bacterial and viral agents, and stem cells including embryonic and adult stem cells and pathogen cells. The present invention provides, therefore, methods of treatment, diagnosis and undertaking research and compositions comprising demibodies useful for same.
    Type: Application
    Filed: November 29, 2006
    Publication date: May 21, 2009
    Applicant: The University of Sydney
    Inventors: Richard Ian Christopherson, Jacqueline Mary Matthews, Joel Peter MacKay
  • Publication number: 20020019018
    Abstract: A method can identify a type of leukemia in a human subject. A biological sample from the human subject that contains CD antigens is obtained. The sample is contacted with an array of immunoglobulin molecules. Each immunoglobulin in the array, with the exception of one or more negative controls, is capable of interaction with a CD antigen on one or more types of leukemia cells. The pattern of interaction between the immunoglobulin molecules and the CD antigens in said sample is then determined, thereby providing an immunophenotype of the cells which is characteristic of the type of leukemia.
    Type: Application
    Filed: June 25, 2001
    Publication date: February 14, 2002
    Inventors: Richard Ian Christopherson, Cristobal Guillermo Dos Remedios